Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: Contributions of type II topoisomerase mutations and efflux to levels of resistance

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 11, 2000, Pages 3049-3054

  Bast, D J ^a   Low, D E ^a   Duncan, C L ^a   Kilburn, L ^a   Mandell, L A ^a   Davidson, R J ^a   De Azavedo, J C S ^a  

^a MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING); GATIFLOXACIN; GEMIFLOXACIN; GREPAFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RESERPINE; SPARFLOXACIN; TROVAFLOXACIN; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; AMINO ACID TRANSPORT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; GENE MUTATION; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE;

AMINO ACID SUBSTITUTION; ANTI-INFECTIVE AGENTS; BACTERIAL PROTEINS; BIOLOGICAL TRANSPORT, ACTIVE; CIPROFLOXACIN; DNA GYRASE; DNA TOPOISOMERASE IV; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; DRUG RESISTANCE, MICROBIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; PHENOTYPE; STREPTOCOCCUS PNEUMONIAE;

EID: 0033744709     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.11.3049-3054.2000     Document Type: Article

References (29)

1. Fluoroquinolones resistance among recent clinical isolates of Streptococcus pneumoniae
2. Community-acquired pneumonia in adults: Guidelines for management. The Infectious Diseases Society of America
3. Community-acquired pneumonia
4. Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae
5. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network
6. In vitro development of resistance to five quinolones and amoxicillin-clavulanate in Streptococcus pneumoniae
7. DNA gyrase, topoisomerase IV, and the 4-quinolones
8. Quaternary changes in topoisomerase II may direct orthogon movement of two DNA strands
9. Primary targets of fluoroquinolones in Streptococcus pneumoniae
10. Identification of an efflux pump gene, pmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae
11. Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro
12. High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA
13. Prevalence of gyrA, gyrB, parC, and pare mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from worldwide surveillance studies during the 1997-1998 respiratory season
14. Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci
15. Crystal structure of the breakage-reunion domain of DNA gyrase
16. Ser-127-to-Leu substitution in the DNA gyrase B subunit of Streptococcus pneumoniae is implicated in novobiocin resistance
17. ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype
18. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob. Agents Chemother
19. Cloning and characterization of the parC and pare genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: Role in fluoroquinolone resistance
20. Targeting ofDNA gyrase in Streptococcus pneumoniae by sparfloxacin: Selective targeting of gyrase or topoisomerase IV by quinolones
21. DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae
22. Characterization of a mutation in the pare gene that confers fluoroquinolone resistance in Streptococcus pneumoniae
23. Contribution of topoisomerase IV and DNA gyrase mutations in Streptococcus pneumoniae to resistance to novel fluoroquinolones
24. Activities of new fluoroquinolones against fluoroquinolone-resistant pathogens of the lower respiratory tract
25. Sparfloxacin resistance in clinical isolates of Streptococcus pneumoniae: Involvement of multiple mutations in gyrA and parC genes
26. Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro
27. ParC and GyrA may be interchangeable initial targets of some fluoroquinolones in Streptococcus pneumoniae
28. Active efflux as a mechanism of resistance to ciprofloxacin in Streptococcus pneumoniae